3415A 3 Ave NW, Calgary, Alberta, T2N 0M4, Canada

Patient Name: Patient, Name
Specimen ID (SID): 24-123-123456
DOB: 01-Jan-2000
PHN: AB 0000000
Reason for Testing: GI ulcers
Relevant Medications: -

External SID: 123456789
Doctor: Dr. Doctor
Report Date: 06-Mar-2025

Specimen Type: Plasma
Date/Time Collected: 01-Jan-2024 / 00:00
Specimen Source: MitogenDx

Interferon Panel

Laboratory Developed Test (LDT)

Analyte	Results (pg/ml)		Reference Interval†
TYPE I INTERFERONS			
IFNα2*	191	**HIGH**	0 - 103
IFNβ	33.0	**HIGH**	0 - 30.0
IFNε	1660	**HIGH**	0 - 1138
IFNω	52.1	**HIGH**	0 - 28.0
TYPE II INTERFERONS			
IFNγ	2.0		0 - 3.1
IFNγR1	54.8	**LOW**	56 - 158
TYPE III INTERFERONS			
IFNλ1*	< 7.2		0 - 7.2
IFNλ2*	63.5	**HIGH**	0 - 37.0
IFNλ3*	30.6	**HIGH**	0 - 16.4

Sample Comments:

-

Results Interpretation:

These results indicate elevated levels of type I and type III interferons, which could suggest an active inflammatory or anti-viral response, particularly at mucosal surfaces. Low levels of soluble IFNγ receptor 1 was observed, which could indicate altered regulation of type II interferon signaling.

Disclaimer:

The interpretation of these test results should be correlated with clinical findings and other diagnostic tests. Biomarker levels can vary due to many biological, physiological, and diurnal factors; their clinical significance must be assessed by a qualified healthcare professional. This information is not intended to be used as the sole basis for diagnosis or treatment decisions.

Reviewed by: DP

Eve Technologies Corporation is a CLIA certified High Complexity International Laboratory

† Reference intervals defined as the 15th percentile (low) and 85th percentile (high) of the total sample distribution.

* Upper reference limit defined as the lower limit of quantification (LLOQ) for this analyte.